VYGR Voyager Therapeutics, Inc.
Healthcare$3.83+0.79%ClosedMarket Cap: $231.4M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.31
P/S
6.34
EV/EBITDA
-1.85
DCF Value
$-4.79
FCF Yield
-56.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.4%
Operating Margin
-349.2%
Net Margin
-319.6%
ROE
-56.0%
ROA
-53.2%
ROIC
-60.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $2.6M | 64.1% | $-30.3M | $-27.9M | $— | — |
| Q4 null | $15.3M | 100.0% | $-29.9M | $-27.4M | $— | — |
| FY null | $40.4M | 100.0% | $-131.8M | $-119.7M | $— | — |
| Q3 null | $13.4M | 100.0% | $-30.6M | $-27.9M | $— | — |
| Q2 null | $5.2M | 100.0% | $-36.6M | $-33.4M | $— | — |
| Q1 null | $6.5M | 100.0% | $-34.7M | $-31.0M | $— | — |
| Q4 null | $6.3M | 100.0% | $-38.3M | $-34.5M | $— | — |
| FY null | $80.0M | 100.0% | $-83.3M | $-65.0M | $— | — |
| Q3 null | $24.6M | 100.0% | $-13.8M | $-9.0M | $— | — |
| Q2 null | $29.6M | -8.0% | $-15.0M | $-10.1M | $— | — |
| Q1 null | $19.5M | 93.9% | $-16.2M | $-11.3M | $— | — |
| Q4 2023 | $90.1M | 98.5% | $54.1M | $56.4M | $1.25 | — |